ABSTRACT: Carbon monoxide is a product of haem degradation by haem oxygenase (HO), activated by inflammatory cytokines and oxidants. This study examined whether allergen challenge can increase exhaled CO levels, as a reflection of HO activation.
There is considerable evidence for airway inflammation and oxidative stress in patients with asthma, even when the disease is mild [1, 2] . Bronchoalveolar lavage (BAL) and bronchial biopsy studies have demonstrated the infiltration of activated inflammatory cells in the airway mucosa and there is a broad relationship between the intensity of inflammation and the clinical severity of asthma. Inhalation of allergen provides a model of asthmatic inflammation, as it provokes an early fall in forced expiratory volume in one second (FEV1) owing to the release of bronchoconstrictor mediators, such as histamine, leukotrienes and prostaglandins [3] , and a late asthmatic response which is associated with a prolonged bronchoconstriction, influx of inflammatory cells [4] and mediators [5±7] and an increase in the oxidative stress in the airway.
It is becoming clear that some oxidant-induced mediators and enzymes, such as haem oxygenase (HO), may also play a vital role in the airway protective response to oxidative stress. Two isoforms of HO have been described: the constitutive HO-2, which is highly expressed in the brain and testes, and the inducible HO-1, which is ubiquitously distributed. The latter is activated by a variety of pro-inflammatory cytokines [8, 9] , nitric oxide [10, 11] , hydrogen peroxide, endotoxin [12] , and oxidants [13] and is an important part of a protective response to oxidative stress [14, 15] .
Carbon monoxide is a product of haem degradation by HO and is recognized as an important signalling molecule [16, 17] . Recently, elevated levels of CO have been found in the exhaled air of asthmatic patients and may reflect the degree of HO-1 induction [18, 19] .
NO is a gas produced by several types of pulmonary cells, including inflammatory, endothelial and airway epithelial cells [20] . Elevated levels of exhaled NO in asthma [21, 22] and bronchiectasis [23] are likely to be due to the activation of the inducible form of NO synthase (iNOS) [24] , and therefore, reflect airway inflammation. A six-fold increase in iNOS expression [7] and elevated levels of exhaled NO [25, 26] have been shown following allergen challenge, confirming the possible role of NO as a noninvasive marker of inflammation.
It was hypothesized that elevated levels of exhaled CO in patients with asthma would be further increased after allergen challenge, as a reflection of HO-1 induction by inflammatory cytokines and oxidative stress; therefore, exhaled CO levels were measured and compared with the levels of exhaled NO.
Subjects and methods

Patients
Eighteen asthmatic subjects aged 272 yrs had a positive cutaneous response (skin-prick test >3 mm weal) to common aeroallergens (cat dander, house dust mites, grass pollen). All had FEV1 values >80% of predicted normal and provocative concentration of histamine causing a 20% fall in FEV1 (PC20) values of > 0.03 mg . mL -1 and did not require corticosteroid treatment in the 3 months before the study. None of the 37 nonsmoking controls (20 males, aged 332.8 yrs) had a history of respiratory or cardiovascular disease or was receiving long-term medication. There was no history of upper respiratory tract infection for at least 4 weeks before the study in any of the studied patients.
Subjects did not consume any caffeine for 2 h or inhaled b 2 -agonists for 8 h before challenge. The smoking status of all the subjects was confirmed by nicCheck I (DynaGen, Cambridge, MA, USA), which detects nicotine and its metabolites in the urine. Active and passive smokers (smoke exposure for >30 min . day -1 ) were excluded from the study. All patients had at least 1 h rest before allergen challenge, in order to eliminate the effect of any possible exposure to high CO concentrations during their journey to the hospital.
Allergen challenge
The subjects were challenged with the allergen that caused the largest weal on skin-prick tests. Allergen inhalation tests were performed using a nebulizer (Dosimeter MB3; MEFAR Electromedical, Bovezzo, Italy) with an output of 200 mL. Freeze-dried allergen extracts (Aquagen SQ; Allerayde, Nottingham, UK) were diluted to give final concentrations of 200, 1,000, 2,500, 5,000, 12,500, 25,000 and 50,000 IU . mL -1 . The initial dose for the allergen inhalation test was 200 IU . mL -1 , and FEV1 was measured 5 and 10 min after each dose. FEV1 was measured using a dry wedge spirometer (Vitalograph, Buckingham, UK). Serially increasing doses of allergen were inhaled and the cumulative dosage resulting in a 15% reduction in FEV1 at 10 min was recorded. FEV1 was measured at 5, 10, 20, 30, 45 and 60 min, then at 30-min intervals until 3 h, then at 4, 5, 6, 7, 8, 9, 10 and 20 h. An early asthmatic response was defined as a >15% fall in FEV1 (postsaline FEV1) at 10 min after antigen challenge and a late asthmatic response as a >15% fall in FEV1 from baseline on three occasions (postsaline FEV1) 4±10 h after challenge.
Histamine challenge
Histamine challenge was performed with doubling concentrations of histamine in the range 0.06±32 mg . mL -1 . After an initial 0.9% saline inhalation, patients were exposed to doubling concentrations of histamine delivered as five breaths from a dosimeter (Dosimeter MB3) at 3-min intervals until FEV1 fell by >20% from the postsaline value. FEV1 was measured 2 min after each inhalation and salbutamol relief was administered when PC20 was reached.
Exhaled carbon monoxide
Exhaled CO was measured by a modified analyser (EC50-MICRO Smokerlyzer CO monitor; Bedfont Scientific, Kent, UK) sensitive to CO from 1±500 parts per million (ppm), adapted for online recording of CO concentration. The subjects exhaled slowly from total lung capacity (TLC) over 20±30 s with a constant flow (5±6 L . min -1 ) into the analyser to standardize exhalation flow rate and minimize the effect of flow dependency on the final exhaled CO levels [27] , and against a resistance generating a mouth pressure of 0.40.05 kPa (360.4 mmHg) shown previously to close the soft palate, thus eliminating ambient and nasal contamination of exhaled air [28] . Two successive recordings were made and the maximum values were used in all calculations. Ambient CO levels were recorded before each measurement.
Exhaled nitric oxide
Exhaled NO was measured using a modified chemiluminescence analyser (model LR2000; Logan Research, Rochester, UK), sensitive to NO from 1±5,000 parts per billion (ppb) and with a resolution of 0.3 ppb, which was designed for online recording of exhaled NO concentrations, as described previously [29] . The analyser was calibrated using certified NO mixtures (90 ppb and 436 ppb) in nitrogen (BOC Special Gases, Guildford, UK). Measurements of exhaled NO were made by slow exhalation (5±6 L . min 
Experimental protocol
Fifteen asthmatic patients were admitted to the Clinical Studies Unit (CSU), Royal Brompton Hospital, for an allergen challenge. Exhaled CO and NO were measured at baseline, at 5, 10, 20, 30, 45 and 60 min, then at 30-min intervals until 3 h, then at 4, 5, 6, 7, 8, 9, 10 and 20 h. Cardiac frequency, blood pressure and FEV1 were monitored until they returned to baseline values. In addition, two of the patients who were submitted to the allergen challenge and three other asthmatic patients underwent histamine challenge. Exhaled CO was measured at baseline, every 2 min after inhalation and every 30 min for up to 2 h after salbutamol administration. FEV1 was monitored every 2 min until a return of baseline FEV1.
Statistics
All results were expressed as means6SEM. Comparisons between groups were made by two-way analysis of variance (ANOVA) with Bonferroni's correction for multiple comparisons. The relationships between exhaled CO, NO and change in FEV1 were tested with the linear correlation coefficient. The cumulative effect of allergen challenge on exhaled CO and NO was expressed as the area under the curve (AUC). A p-value <0.05 was considered significant.
Results
Ten asthmatic patients had both an early and a late asthmatic response (dual responders) and five had an isolated early response (single responders).
Baseline exhaled CO levels were equally elevated in dual responders (4.90.3 ppm), single responders (4.70.3 ppm) and asthmatic subjects who underwent histamine challenge (4.20.2 ppm) compared with a control group of 37 nonsmoking subjects (2.10.2 ppm, p<0.05).
Exhaled CO levels were elevated during both the early (maximum change from baseline 3467% at 60 min, AUC 111 au; fig. 1a ) and late asthmatic reaction in dual responders (maximum change from baseline 6912% at 6 h, AUC 291 au). The maximum fall in FEV1 was 233% at 10 min and 289% at 9 h after allergen challenge.
Exhaled CO was also elevated in single responders during the early asthmatic reaction (maximum change from baseline 302% at 60 min; AUC 31 au; fig. 1b ) and between 4 and 10 h after allergen inhalation (AUC 201 au, p<0.05). The increase in exhaled CO was lower in single responders than in dual responders both during the early and late asthmatic reaction.
Exhaled CO returned to baseline by 20 h in both dual and single responders. There was no correlation between the magnitude of the CO response and FEV1 change in either group.
Baseline exhaled NO levels were comparable in dual (20.61.5 ppb) and single responders (20.61.8 ppb).
In patients who had a dual response there was a significant increase in exhaled NO during the late reaction (mean maximum increase 50.211.8% 10 h after challenge; fig. 2a ).
In single responders there was no significant change in exhaled NO at any of the time points studied (fig. 2b ).
Histamine challenge
In five patients histamine challenge produced a concentration-dependent reduction in FEV1 with maximum fall of 287%, but with no change in CO (maximum CO fall 41%, p>0.05) and without subsequent changes at 30, 60, 90 or 120 min following salbutamol administration (data not shown). 
Discussion
The results show that exhaled CO levels are increased during both the late and early asthmatic reaction independently of acute changes in airway calibre, but precede the fall in FEV1 during the late asthmatic reaction in dual responders. Exhaled NO levels were elevated in dual responders after the late fall in FEV1, whereas single responders showed no significant increase in exhaled NO.
The activation of HO-1 by prostaglandins [30] released by mast cells during the early asthmatic reaction [3, 31] may explain the elevated levels of exhaled CO during this phase. The absence of significant changes in exhaled NO levels is possibly due to the inability of prostaglandins and other compounds released during the early reaction, such as leukotrienes and histamine, to activate iNOS.
Much higher levels of exhaled CO and NO during the late asthmatic reaction may also be due to HO-1 activation by inflammatory cytokines such as interleukin (IL)-1, IL-6, tumour necrosis factor (TNF-a) [32, 33] and iNOS activation by IL-1 and TNF-a [34, 35] which are abundant in BAL at the time of the late asthmatic reaction [36, 37] . Increased production of oxidants by incoming inflammatory cells and tissue cells may contribute to HO-1 activation [38] , explaining higher CO levels in dual responders than in single responders.
HO-1 may be induced in various cells in the respiratory tract, such as epithelial cells and infiltrating inflammatory cells [39] . In a previous study, increased expression of HO-1 was shown in the alveolar macrophages of asthmatic patients when compared with normal subjects [19] . HO-1 activation may be the result of increased oxidative stress. The induction of HO-1 participates in the resolution of acute inflammation and plays a protective role in oxidant-induced cellular injuries [40] .
No change was seen in CO during histamine-induced bronchoconstriction, indicating that bronchoconstriction itself does not influence CO levels and, therefore, the elevation of CO levels observed during allergen challenge is probably due to inflammation and oxidative stress, rather than changes in airway calibre.
There is evidence that NO induces HO-1 activity and CO production in vascular muscle cells [11] . This study has confirmed previously published data [25] showing elevated exhaled NO levels during the late asthmatic reaction in dual responders only, with a peak at 10 h after allergen challenge, which may be a reflection of iNOS induction. Indeed, a six-fold increase in iNOS expression has been shown at 4 h following allergen challenge in sensitized rats [7] , whilst exhaled CO in the present study was highest at 6 h. This may be due to a different time response of HO-1 and iNOS to their common activating inflammatory cytokines, IL-1 and TNF-a. Furthermore, high levels of CO during the late reaction may inhibit iNOS activity [41] , retarding the rise in NO. In single responders, exhaled CO but not NO [25] is elevated during the late reaction, which may indicate that CO is a more sensitive index of inflammation.
Measurement of exhaled carbon monoxide may be another means of detecting and monitoring cytokine-and oxidant-mediated inflammation and of assessing antiinflammatory treatments. In addition to its potential as a marker of inflammation, it is possible that the increase in exhaled carbon monoxide may be of pathophysiological significance. It will be necessary to intervene with specific inhibitors of haem oxygenase in the future in order to explore this possibility further.
